
Eliem Therapeutics (NASDAQ:ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP).
During the Phase 2a proof-of-concept trial evaluating ETX-810 inchronic lumbosacral radicular pain (LSRP), 149 patients are enrolled at sites across the United States.